Improved Lipid and Lipoprotein Profile, Hepatic Insulin Sensitivity, and Glucose Tolerance in 11beta-hydroxysteroid Dehydrogenase Type 1 Null Mice
Overview
Affiliations
Excess tissue glucocorticoid action may underlie the dyslipidemia, insulin resistance, and impaired glucose tolerance of the metabolic syndrome. 11beta-Hydroxysteroid dehydrogenase type 1 (11beta-HSD-1) catalyzes conversion of circulating inert 11-dehydrocorticosterone into active corticosterone, thus amplifying local intracellular glucocorticoid action, particularly in liver. The importance of 11beta-HSD-1 in glucose homeostasis is suggested by the resistance of 11beta-HSD-1(-/-) mice to hyperglycemia upon stress or obesity, due to attenuated gluconeogenic responses. The present study further investigates the metabolic consequences of 11beta-HSD-1 deficiency, focusing on the lipid and lipoprotein profile. Ad lib fed 11beta-HSD-1(-/-) mice have markedly lower plasma triglyceride levels. This appears to be driven by increased hepatic expression of enzymes of fat catabolism (carnitine palmitoyltransferase-I, acyl-CoA oxidase, and uncoupling protein-2) and their coordinating transcription factor, peroxisome proliferator-activated receptor-alpha (PPARalpha). 11beta-HSD-1(-/-) mice also have increased HDL cholesterol, with elevated liver mRNA and serum levels of apolipoprotein AI. Conversely, liver Aalpha-fibrinogen mRNA levels are decreased. Upon fasting, the normal elevation of peroxisome proliferator-activated receptor-alpha mRNA is lost in 11beta-HSD-1(-/-) mice, consistent with attenuated glucocorticoid induction. Despite this, crucial oxidative responses to fasting are maintained; carnitine palmitoyltransferase-I induction and glucose levels are similar to wild type. Refeeding shows exaggerated induction of genes encoding lipogenic enzymes and a more marked suppression of genes for fat catabolism in 11beta-HSD-1(-/-) mice, implying increased liver insulin sensitivity. Concordant with this, 24-h refed 11beta-HSD-1(-/-) mice have higher triglyceride but lower glucose levels. Further, 11beta-HSD-1(-/-) mice have improved glucose tolerance. These data suggest that 11beta-HSD-1 deficiency produces an improved lipid profile, hepatic insulin sensitization, and a potentially atheroprotective phenotype.
Targeting osteoblastic 11β-HSD1 to combat high-fat diet-induced bone loss and obesity.
Zhong C, Li N, Wang S, Li D, Yang Z, Du L Nat Commun. 2024; 15(1):8588.
PMID: 39362888 PMC: 11449908. DOI: 10.1038/s41467-024-52965-4.
Schill R, Visser J, Ashby M, Li Z, Lewis K, Morales-Hernandez A Front Endocrinol (Lausanne). 2024; 15:1397081.
PMID: 38887268 PMC: 11180776. DOI: 10.3389/fendo.2024.1397081.
A genetic mouse model of lean-NAFLD unveils sexual dimorphism in the liver-heart axis.
Burelle C, Clapatiuc V, Deschenes S, Cuillerier A, De Loof M, Higgins M Commun Biol. 2024; 7(1):356.
PMID: 38519536 PMC: 10959946. DOI: 10.1038/s42003-024-06035-6.
G6PC1 and G6PC2 influence G6P flux but not HSD11B1 activity.
Hawes E, Boortz K, Oeser J, ORourke M, OBrien R J Mol Endocrinol. 2023; 71(4).
PMID: 37855366 PMC: 10616506. DOI: 10.1530/JME-23-0070.
Devang N, Banjan B, V K P J Diabetes Metab Disord. 2023; 22(1):657-672.
PMID: 37255841 PMC: 10225457. DOI: 10.1007/s40200-023-01191-8.